Morocco Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Morocco Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Morocco Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: The Moroccan government's decision to reimburse generic Sovaldi (sofosbuvir) along with the incorporation of students into it medical coverage scheme highlights its commitment to increasing the population's access to healthcare - a positive to drugmakers. However, in the long-term, the uncertainty surrounding drug prices will still remain an issue for drugmakers, hindering the country's attractiveness to drug companies whose portfolios contain high value drugs.

Headline Expenditure Projections

  • Pharmaceuticals: MAD12.52bn (USD1.49bn) in 2014 to MAD13.39bn (USD1.40bn) in 2015; +6.8% in local currency terms and -5.9% in US dollar terms. Forecast revised upwards from last quarter.

  • Healthcare: MAD55.63bn (USD6.61bn) in 2014 to MAD59.35bn (USD6.21bn) in 2015; +6.7% in local currency terms and -6.1% in US dollar terms. Forecast revised downwards from last quarter.

Headline Pharmaceuticals & Healthcare Forecasts (Morocco 2013-2019)
2013 2014 2015f 2016f 2017f 2018f 2019f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 1.341 1.489 1.401 1.455 1.616 1.785 1.933
Pharmaceutical sales, % of GDP 1.25 1.36 1.37 1.38 1.39 1.39 1.39
Pharmaceutical sales, % of health expenditure 21.5 22.5 22.6 22.5 22.3 22.1 21.9
Health spending, USDbn 6.240 6.610 6.210 6.468 7.257 8.084 8.827

Risk/Reward Index

Morocco is viewed as a moderately attractive pharmaceutical market in the Middle East and Africa (MEA) region. In our Q116 proprietary Pharmaceutical Risk/Reward Index (RRI) table, Morocco remains the 14th most attractive market in the region out of the 31 countries assessed, although it improves on its previous score at 43.0 out of 100 (40.6 in Q415). The market's constraints include low per capita consumption and an underdeveloped reimbursement system, although such factors are to a degree offset by a relatively predictable operating environment.

Latest Updates

  • In November 2015, Private equity firm Abraaj Group acquired a majority stake in the Centre de Traitement Al Kindy in Casablanca, as well as in the Clinique Specialisee Menara in Marrakech. Al Kindy and Menara together form the largest private integrated network of imaging diagnostics and cancer treatment centres in Morocco, with 12 doctors expected to collectively treat more than 10,000 patients in 2015.

  • In November 2015, a generic version of hepatitis c blockbuster drug Sovaldi (sofosbuvir) began local manufacturing in morocco which will be fully reimbursed by the National Social Security Fund (NSSF).

  • In September 2015, Morocco's Health Ministry issued a decree regulating the prices of 104 types of drugs. The ministry proposed the reduction in prices of these medicines by between 30% and 40% for consumers, while their prices for public hospitals are to be reduced between 40% and 50%.

  • UAE-based developer Tasweek Real Estate Development and Marketing will open its Marrakesh Healthcare City residential and healthcare complex in Morocco in December 2015.

  • In September 2015, Morocco took a major step in expanding its universal health coverage by incorporating students at universities and vocational training centres into its medical coverage scheme. The new health insurance law will become effective at the start of the forthcoming school year .

BMI Economic View

Morocco's economic growth will slow down in 2016, as agricultural output reverts to the mean following a record-high harvest in 2015, impacting private consumption and headline growth. Nevertheless, the country will remain on track towards economic diversification, attracting high levels of FDI, as it benefits from its relative security, favourable geographic location, and the government's pro-investment stance.

BMI Political View

Morocco will continue to consider Western Sahara as a core issue of its foreign policy over the coming years, increasing the risk of disputes with third parties, and potentially impacting the country's attractiveness for foreign investors.

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Operational Risk
14
Industry Forecast
16
Pharmaceutical Market Forecast
16
Table: Pharmaceutical Sales, Historical Data And Forecasts (Morocco 2011-2019)
18
Healthcare Market Forecast
19
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2011-2019)
20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2011-2019)
21
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2011-2019)
21
Prescription Drug Market Forecast
22
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Morocco 2011-2019)
23
Patented Drug Market Forecast
24
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Morocco 2011-2019)
25
Generic Drug Market Forecast
26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Morocco 2011-2019)
28
OTC Drug Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Morocco 2011-2019)
30
Pharmaceutical Trade Forecast
31
Table: Pharmaceutical Trade Data And Forecasts (Morocco 2013-2019)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (Morocco 2013-2019)
33
Key Risks To BMI's Forecast Scenario
34
Macroeconomic Forecasts
36
Economic Analysis
36
Expenditure Breakdown
38
Table: Various Countries, Real GDP Growth, % chg y-o-y
43
Table: Economic Activity (Morocco 2010-2019)
43
Industry Risk Reward Indices
44
Middle East and Africa Risk/Reward Index
44
Morocco Risk/ Reward Index
51
Rewards
51
Risks
52
Market Overview
54
Industry Trends And Developments
55
Epidemiology
55
Healthcare Sector
57
Table: Healthcare Resources (Morocco 2009-2014)
61
Table: Healthcare Personnel (Morocco 2009-2014)
62
Table: Healthcare Activity (Morocco 2009-2014)
62
Healthcare Insurance
62
Recent Health Insurance Developments
64
Research & Development
67
Clinical Trials
68
Regulatory Development
69
Intellectual Property Regime
70
Pricing Regime
70
Reimbursement Regime
73
Competitive Landscape
76
Pharmaceutical Industry
76
Table: Morocco's Select Pharmaceutical Industry Indicators
76
Table: Members Of MIS, 2011
77
Table: Members Of AMIP, 2011
78
Domestic Pharmaceutical sector
78
Foreign Pharmaceutical Companies
79
Pharmaceutical Wholesale
82
Pharmaceutical Retail
83
Company Profile
84
Sothema
84
Laprophan
87
Promopharm
90
Sanofi
92
Pfizer
96
GlaxoSmithKline
99
Ranbaxy
101
Demographic Forecast
104
Demographic Outlook
104
Table: Population Headline Indicators (Morocco 1990-2025)
105
Table: Key Population Ratios (Morocco 1990-2025)
105
Table: Urban/Rural Population & Life Expectancy (Morocco 1990-2025)
106
Table: Population By Age Group (Morocco 1990-2025)
106
Table: Population By Age Group % (Morocco 1990-2025)
107
Glossary
109
Methodology
111
Pharmaceutical Expenditure Forecast Model
111
Healthcare Expenditure Forecast Model
111
Notes On Methodology
112
Risk/Reward Index Methodology
113
Index Overview
114
Table: Pharmaceutical Risk/Reward Index Indicators
114
Indicator Weightings
115

The Morocco Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Morocco Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Morocco pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Morocco, to test other views - a key input for successful budgeting and strategic business planning in the Moroccan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Moroccan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Morocco.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.